（文章来源：证券日报） 证券日报网讯 1月7日，海辰药业在互动平台回答投资者提问时表示，公司硫化锂中试线产品各项参数 指标已达到要求，即将安排送样。四川洛辰是公司控股子公司安庆汇辰与赛科动力的合资公司，双方一 直在固态电池粘结剂的小试开发上紧密合作，该项目目前还处于小试开发阶段。 ...

格隆汇1月7日丨海辰药业(300584.SZ)在投资者互动平台表示，公司硫化锂中试线产品各项参数指标已 达到要求，即将安排送样。四川洛辰是公司控股子公司安庆汇辰与赛科动力的合资公司，双方一直在固 态电池粘结剂的小试开发上紧密合作，该项目目前还处于小试开发阶段。 ...

海辰药业（300584.SZ）1月7日在投资者互动平台表示，公司硫化锂中试线产品各项参数指标已达到要 求，即将安排送样。四川洛辰是公司控股子公司安庆汇辰与赛科动力的合资公司，双方一直在固态电池 粘结剂的小试开发上紧密合作，该项目目前还处于小试开发阶段。 每经AI快讯，有投资者在投资者互动平台提问：近期硫化物固态电池产业化加速，公司两个领域的进 展备受市场关注，1. 硫化锂方面，请问目前中试产能利用率（如日产量）、产品纯度？是否已送样至电 池企业（如赛科自身或其他合作电池厂）验证？2026年百吨级产能爬坡节奏？2. 固固接触粘接剂方面， 洛辰的小试工艺是否完成？粘接强度、界面阻抗是否符合行业领先水平？赛科动力在电池系统集成方面 的经验，是否为粘接剂量产提供支持？是否已送样电池厂性能验证？ （文章来源：每日经济新闻） ...

Group 1 - Company Gongchuang Turf (605099.SH) stated that the impact of domestic football events on its operations and performance is minimal, as its main business of artificial turf has a low revenue contribution from domestic sports grass [1] - Company Anglikang (002940.SZ) confirmed that its innovative drug project ALK-N001 is still in Phase I clinical trials, indicating a long R&D cycle and significant investment [2] - Company Yiwei Lithium Energy (300014.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image [3] Group 2 - Company Chaohongji (002345.SZ) also intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and improve competitiveness [4] - Company Dexin Technology (603032.SH) clarified that its subsidiary's sales revenue from products used in solid-state battery production is less than 1% of total revenue, emphasizing its focus on quality service [5] - Company Changshan Pharmaceutical (300255.SZ) announced that its application for the marketing authorization of Aibennapeptide injection for type 2 diabetes has been accepted, but the approval timeline remains uncertain [6] Group 3 - Company Baili Electric (600468.SH) reported that its revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue [7] - Company Chutianlong (003040.SZ) is exploring digital currency projects but faces risks related to new technology development and commercial application [8] - Company Dongxing Medical (301290.SZ) signed contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan, enhancing its R&D capabilities [9] Group 4 - Company Maixinlin (688685.SH) announced that its subsidiary signed contracts for computing power services worth 1.184 billion yuan, expected to positively impact future performance [10] - Company Haichen Pharmaceutical (300584.SZ) reported that its solid-state battery-related business has not yet generated revenue, which does not significantly affect overall performance [11] - Company Filinger (603226.SH) is undergoing stock trading suspension for investigation due to significant price deviations from fundamentals [12] Group 5 - Company Zhongdian Port (001287.SZ) disclosed that the National Integrated Circuit Fund reduced its stake by 1%, now holding 8.97% of the company [13] - Company Huasheng Co., Ltd. (600156.SH) is planning to acquire 100% of Yixin Technology, leading to a stock suspension for up to 10 trading days [14] - Company Jianghuai Automobile reported a 3.52% year-on-year decline in May sales, with new energy vehicle sales down 57.81% [15] - Company Aonong Biological reported a 9.44% year-on-year increase in May pig sales, with a total of 156,200 pigs sold [16]

Group 1 - Jinling Sports announced that its convertible bonds experienced significant abnormal fluctuations, with a cumulative price deviation of 39.14% over three consecutive trading days, indicating potential irrational trading behavior and high market risk [3] - Haichen Pharmaceutical reported that its solid-state battery-related business has not yet generated revenue, and the project faces risks related to industrialization and commercialization due to macroeconomic and market environment changes [4] - Jinying Co. confirmed that there have been no significant changes in its daily operations, with stable production costs and sales, and no major adjustments in market conditions or industry policies [5] Group 2 - Lingyi Technology received acceptance from the Shenzhen Stock Exchange for its plan to issue convertible bonds and acquire a 66.46% stake in Jiangsu Kedasitern Automotive Technology Co., Ltd., along with raising supporting funds [6] - Sichuan Road and Bridge announced plans to acquire 100% equity of Chengdu Xinzhu Transportation Technology Co., Ltd. and other related assets to enhance its bridge component business and improve market competitiveness [7] Group 3 - Jianghuai Automobile reported May sales of 33,400 vehicles, a year-on-year decrease of 3.52%, with new energy vehicle sales dropping by 57.81% [9] - Aonong Biological announced May sales of 156,200 pigs, a year-on-year increase of 9.44%, with a total stock of 536,400 pigs at the end of May, reflecting a 22.56% year-on-year increase [10] - Juxing Agriculture reported May sales of 328,000 pigs, a significant year-on-year increase of 61.5%, generating sales revenue of 579 million yuan [12] Group 4 - Hongyuan Electronics' controlling shareholders plan to reduce their holdings by up to 1% of the company's total shares due to personal funding needs [14] - Kaichun Co. announced an increase in its share repurchase price limit from 26.625 yuan to 40 yuan per share, effective June 10, 2025 [16]

Core Viewpoint - Haicheng Pharmaceutical has established a joint venture in the solid-state battery adhesive business, but this segment has not yet generated revenue, thus not significantly impacting the company's overall performance [1] Company Summary - Haicheng Pharmaceutical (300584.SZ) has set up a joint venture with Saike Power through its subsidiary Anqing Huicheng to enter the solid-state battery adhesive market [1] - The solid-state battery-related business has not yet formed any revenue, indicating that it is still in the early stages of development [1] Industry Summary - The project faces risks related to industrialization and commercialization not meeting expectations due to factors such as macroeconomic conditions, industry policies, and market environment changes [1]